Targeted therapies in the treatment of advanced hepatocellular carcinoma.

Authors

Zhengyu Wei, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, NJFollow
Cataldo Doria, Jefferson Medical College - Thomas Jefferson University HospitalFollow
Yuan Liu, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, NJ

Document Type

Article

Publication Date

1-1-2013

Comments

This article has been peer reviewed. It was published in: Clinical Medicine Insights. Oncology

2013 May 20;7:87-102

The published version is available at DOI: 10.4137/CMO.S7633. Copyright © Libertas Academica

Abstract

Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been a major worldwide health problem with more new cases being diagnosed each year. The current available therapies for patients with advanced HCC are extremely limited. Therefore, it is of great clinical interests to develop more effective therapies for systemic treatment of advanced HCC. Several promising target-based drugs have been tested in a number of clinical trials. One breakthrough of these efforts is the approved clinical use of sorafenib in patients with advanced HCC. Targeted therapies are becoming an attractive option for the treatment of advanced HCC. In this review, we summarize the most recent progress in clinical targeted treatments of advanced HCC.

Recommended Citation

Wei, Zhengyu; Doria, Cataldo; and Liu, Yuan, "Targeted therapies in the treatment of advanced hepatocellular carcinoma." (2013). Department of Surgery Faculty Papers. Paper 88.
https://jdc.jefferson.edu/surgeryfp/88

PubMed ID

23761989